ASX:PNV PolyNovo (PNV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PolyNovo Stock (ASX:PNV) 30 days 90 days 365 days Advanced Chart Get PolyNovo alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.38 million shsAverage VolumeN/AMarket CapitalizationA$1.30 billionP/E Ratio247.31Dividend Yield6.86%Price TargetN/AConsensus RatingN/A Company Overview PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia. Read More Receive PNV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PNV Stock News HeadlinesPolyNovo Initiates Trading Halt Ahead of Clinical Trial AnnouncementSeptember 13 at 2:51 AM | msn.comPolyNovo’s NovoSorb BTM Shows Promising Results in Diabetes-Related Foot Wound HealingSeptember 11, 2025 | tipranks.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …September 16 at 2:00 AM | Weiss Ratings (Ad)ASX biotech chair scoops up more stockSeptember 11, 2025 | msn.comPolyNovo Director Increases Shareholding, Signaling Confidence in FutureSeptember 10, 2025 | tipranks.comPolyNovo (ASX:PNV) Is Up 16.0% After Doubling Earnings Per Share - Has The Bull Case Changed?September 6, 2025 | finance.yahoo.comHealth Check: Polynovo shares go crackers after positive US reimbursement changesSeptember 2, 2025 | msn.comPolynovo shares surge on growth potential from US medicare overhaulSeptember 2, 2025 | za.investing.comSee More Headlines PNV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of PolyNovo own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyNovo investors own include Align Technology (ALGN), Amgen (AMGN), Docusign (DOCU), Panoramic Resources (PAN), Plug Power (PLUG) and Roku (ROKU). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:PNV CIKN/A Webwww.polynovo.com.au Phone61 3 8681 4050FaxN/AEmployees237Year FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.01 Trailing P/E Ratio247.31 Forward P/E RatioN/A P/E Growth2.63Net IncomeA$5.26 million Net Margins5.10% Pretax MarginN/A Return on Equity7.45% Return on Assets0.56% Debt Debt-to-Equity Ratio21.32 Current Ratio3.41 Quick Ratio1.58 Sales & Book Value Annual SalesA$103.23 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow207.50 Book ValueA$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares690,760,000Free FloatN/AMarket CapA$1.30 billion OptionableNot Optionable Beta1.67 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (ASX:PNV) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyNovo Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyNovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
